CAR-T cell therapy for relapsed or refractory myeloid cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment called CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatments. CAR-T cells are specially designed to find and destroy cancer cells. The goal is to see if this therapy is safe and works for patients whose cancer cells have specific markers (CD33, CD123, or CLL-1).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of blood cancer, such as acute myeloid leukemia (AML) or a similar condition, that has not improved after at least two rounds of standard treatment or has come back after treatment.
- Your cancer cells must have at least one of three specific markers: CD33, CD123, or CLL-1 (your doctor can check this with a lab test).
- You must be in generally good health: your heart, lungs, kidneys, and liver should be working well enough, and you should be able to take care of yourself (ECOG score 0-2).
- You cannot have an active infection, severe heart or lung disease, another cancer that is growing, or a weak immune system from conditions like HIV or certain transplants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This Phase 1 trial tests CAR-T cell therapy (immune cells modified to target cancer) in people whose blood cancers came back or didn’t respond to standard treatments. If you qualify, the study aims to see whether this treatment can fight the cancer and how safe it is.
Hear when a new CAR-T trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.